Pa/HDa-216 is a first-in-class, orally administered adjunct to statins to treat the plaques that contribute to atherosclerosis, a major factor in heart attacks and strokes, which are the leading causes of death in the US and worldwide
Pa/HDa-216 significantly reduced arterial plaque in the ApoE-/- mouse model in a study conducted at The Cleveland Clinic.